Hangzhou Diagens Biotechnology (SEHK:2526) has drawn fresh attention after recent price pressure, with the share price down 53% over the past month and 49% over the past 3 months, which has sharpened investor focus on fundamentals.
Short term momentum for Hangzhou Diagens Biotechnology has clearly faded, with the 1 day, 7 day and 30 day share price returns all in decline, even though the year to date share price return of 14.5% still leaves longer term holders in positive territory.
See how Hangzhou Diagens Biotechnology compares with other pressured high-growth stories by reviewing the hand picked 619 high quality undiscovered gems now on Simply Wall St.
After a drop of roughly half in three months, Hangzhou Diagens Biotechnology now trades in a zone where fair value depends on how you weigh its recent HK$240 price against a wide range of intrinsic estimates.
Price-to-Book of 23.5x for Hangzhou Diagens Biotechnology: Is it justified?
On simple book value terms, Hangzhou Diagens Biotechnology looks expensive, with the shares at HK$240 trading on a P/B of 23.5x compared with much lower benchmarks across its sector and peer group.
The P/B ratio compares the market value of the equity to the accounting value of net assets on the balance sheet. For a medical devices and healthcare software player like Hangzhou Diagens Biotechnology, a richer P/B can reflect expectations for future product adoption, intellectual property, and recurring software income that does not fully show up in book value.
The gap is wide. Management is guiding an unprofitable business at present, and the firm reports a decline in Return on Equity of 15.7%, which means current earnings do not support such a premium on a profitability basis. Against that backdrop, investors paying 23.5x book value are putting a high price on future execution and monetisation of its AI imaging and medical device portfolio.
- The stock trades on a P/B of 23.5x.
- The Hong Kong Medical Equipment industry average P/B is 1.5x.
- The peer group average P/B is 14x.
Those comparisons show the valuation mark up is strong. The P/B multiple of 23.5x sits far above both the 1.5x sector average and the 14x peer level, which suggests the market is assigning a much richer value to Hangzhou Diagens Biotechnology than to similar medical equipment stocks.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-book of 23.5x (OVERVALUED)
Still, the current loss of CN¥121.68m and the reliance on Mainland China for all HK$183.31m of revenue leave Hangzhou Diagens Biotechnology exposed if demand softens.
Find out about the key risks to this Hangzhou Diagens Biotechnology narrative.
Next Steps
Mixed signals can feel messy, especially when Hangzhou Diagens Biotechnology carries both pressure points and bright spots, so move fast, pull up the numbers, and weigh the trade offs yourself using the 1 key reward and 1 important warning sign
Looking for more ideas beyond Hangzhou Diagens Biotechnology?
If Hangzhou Diagens Biotechnology feels finely balanced for your portfolio, you might want to broaden your watchlist with other focused ideas that line up more cleanly with your risk and return preferences.
- Target steadier compounding by scanning for proven businesses on our 184 high quality undervalued stocks before the wider market pays attention to them.
- Prioritise resilience by reviewing a curated list of solid balance sheet and fundamentals (207 results) that can help you stress test your capital against tougher conditions.
- Lean into quality with income by assessing a hand picked set of 228 dividend fortresses that could complement more volatile holdings.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com